Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Novo Nordisk Q1 profit...

    Novo Nordisk Q1 profit tops forecast as new diabetes drug Ozempic shines

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-05T09:15:21+05:30  |  Updated On 5 May 2019 9:15 AM IST
    Novo Nordisk Q1 profit tops forecast as new diabetes drug Ozempic shines

    Sales of the treatment, branded Ozempic, rose to 1.4 billion Danish crowns ($209 million) in the quarter, trumping analyst forecasts for 1.3 billion crowns.


    COPENHAGEN: Danish drugmaker Novo Nordisk beat first-quarter operating profit forecasts on Friday, helped by higher sales of its biggest new drug hope, a treatment for type 2 diabetes.


    With Novo's traditional insulin treatments facing U.S. price pressures and close to losing patent protection, the world's biggest maker of diabetes drugs is pinning its hopes a once-a-week injection that helps reduce blood sugar and weight.


    Read Also: Gilead Sciences, Novo Nordisk to initiate clinical collaboration for NASH trial


    Sales of the treatment, branded Ozempic, rose to 1.4 billion Danish crowns ($209 million) in the quarter, trumping analyst forecasts for 1.3 billion crowns.


    Ozempic, the newest drug in the so-called GLP-1 drug class, takes aim at Eli Lilly's Trulicity, which has been taking market share from Novo's former flagship treatment, once-a-day Victoza.


    "Based on our launch of Ozempic in the U.S. we see that we are stopping our loss in market share (of GLP-1 drugs)," Chief Executive Lars Fruergaard Jorgensen told reporters.


    Read Also: Abbott, Novo Nordisk enters partnership to provide digital solution for diabetes management


    However, Ozempic is also eating into sales of Victoza, which fell more than analysts' expected in the quarter, although Jorgensen said the decline was in line with Novo's projections.


    "We have never expected Victoza to keep growing when we launched Ozempic because it is just a much better product," he said.


    Novo shares were steady at 0800 GMT, having recouped early losses.


    GLP-1 drugs, which imitate an intestinal hormone that stimulates the production of insulin, make up a growing share of the diabetes market, and Novo, an early mover together with Eli Lilly, has a 46.1 per cent share of the market.


    The drugs have proved effective in reducing diabetes patients' blood glucose levels and weight and have also showed cardiovascular benefits in studies. But on the downside, they drugs are more expensive than some other treatments.


    Novo's first-quarter operating profit of 14.2 billion crowns beat analysts' average forecast of 13.2 billion crowns, helped by a reversal of some write-downs..


    Read Also: Sanofi, Novo Nordisk Eli Lilly accused of deceptive drug pricing of Insulin


    The company kept its 2019 forecasts for sales growth of 2-5 per cent and operating profit growth of 2-6 per cent, both in local currencies.


    However, sales and operating profit growth in Danish crowns are now expected to be 3 and 5 percentage points higher than the local currency level, respectively, compared with previous guidance of 2 and 4 percentage points higher.


    Novo shares are trading at around 19 times forecast earnings, above the average multiple for the sector of roughly 16 times, according to Eikon Refinitiv data.

    blood sugarCOPENHAGENDanish drugmakerDanish drugmaker Novo Nordiskdiabetesdiabetes drugEikon RefinitivEli LillyGLP 1 drugsinsulininsulin treatmentsLars Fruergaard JorgensenNovo NordiskNovo sharesOzempicsale of new diabetes drugtreatmentTrulicitytype-2 diabetesUnited StatesUSVictoza
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok